IPDQF (Impedimed) Institutional Ownership : 0.00% (As of Apr. 27, 2025)

View and export this data going back to . Start your Free Trial

What is Impedimed Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Impedimed's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Impedimed's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Impedimed's Float Percentage Of Total Shares Outstanding is 0.00%.

Impedimed Institutional Ownership Historical Data

The historical data trend for Impedimed's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impedimed Institutional Ownership Chart

Impedimed Historical Data

The historical data trend for Impedimed can be seen below:

	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	5.87	5.85	5.07	4.48	3.82	3.19	2.89	2.79	2.79	2.79

Impedimed Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Impedimed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (OTCPK:IPDQF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

IPD:Australia

Address

50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008

Website

https://www.impedimed.com

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.